Compass Therapeutics, Inc.
CMPX
$3.72
-$0.06-1.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.31% | 38.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.25% | 8.40% | |||
| Operating Income | -17.25% | -8.40% | |||
| Income Before Tax | -19.53% | -10.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.53% | -10.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.53% | -10.64% | |||
| EBIT | -17.25% | -8.40% | |||
| EBITDA | -17.61% | -8.47% | |||
| EPS Basic | -19.53% | -9.36% | |||
| Normalized Basic EPS | -19.55% | -9.30% | |||
| EPS Diluted | -19.53% | -9.36% | |||
| Normalized Diluted EPS | -19.55% | -9.30% | |||
| Average Basic Shares Outstanding | 0.03% | 1.18% | |||
| Average Diluted Shares Outstanding | 0.03% | 1.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||